Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2024-08-01 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in authorised share capital, issued shares, share options, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements rather than financial performance or management commentary. The document is about share capital changes and confirmations related to securities issuance and treasury shares, which aligns with announcements regarding share issues or capital changes. It is not an annual or interim report, earnings release, or management discussion. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length (8770 characters) and content confirm it is a substantive report on share capital movements, not merely an announcement of a report or a certification.
2024-08-01 English
REVISION OF ANNUAL CAP FOR CONTINUING CONNECTED TRANSACTIONS UNDER THE MASTER SALE AND PURCHASE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the revision of the annual cap for continuing connected transactions under a Master Sale and Purchase Agreement. It discusses the increase in transaction limits for sales of materials between the company and a connected party, including detailed pricing policies, transaction amounts, and internal control measures. The document is structured as a formal announcement to shareholders and the market, referencing Listing Rules implications and internal governance. It does not contain financial statements or comprehensive financial performance data, nor is it a transcript, report, or presentation. It is a regulatory announcement about a connected transaction and revision of transaction limits, which fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Capital/Financing Update or Major Shareholding Notification. The document length is substantial and contains detailed information, but it is not a financial report or earnings release. Therefore, the best classification is Regulatory Filings (RNS).
2024-07-26 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors about a product development update, specifically the approval of a drug registration. It is short (1547 characters) and does not contain financial data, regulatory certifications, or detailed financial reports. It is not an annual or interim report, nor a call transcript or capital update. It is an announcement to inform shareholders and investors about business developments, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-07-23 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding product development updates, specifically the approval of two drugs by the National Medical Products Administration of China. It is not a financial report, earnings release, or regulatory filing related to financial performance or governance changes. The document is short (1776 characters) and serves to inform shareholders and investors about business developments rather than financial results or corporate governance. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous update that does not fit other specific categories. According to the rules, such announcements are classified as Regulatory Filings (RNS).
2024-07-17 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding an update on product development, specifically the approval for drug production and registration. It is not a financial report, earnings release, or regulatory filing related to financial performance. The document is short (1919 characters) and serves to inform shareholders and investors about business developments rather than financial results or governance changes. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is an announcement of business progress, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2024-07-16 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of SSY Group Limited regarding approvals obtained for drug production and registration from the National Medical Products Administration of China. It provides updates on product development and regulatory approvals but does not contain financial statements, detailed financial analysis, or comprehensive report content. The document is relatively short (4209 characters) and serves to inform shareholders and investors about business developments rather than presenting a formal report or financial results. It is not an annual or interim report, earnings release, or any form of detailed financial filing. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The content fits best as a Capital/Financing Update (CAP) or a Regulatory Filing (RNS). However, since it is a voluntary announcement about product development approvals and not about financing or capital structure changes, it does not fit CAP. It is an announcement of business development information, which is typically classified under Regulatory Filings (RNS) as a general announcement that does not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-07-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.